Kite to highlight industry-leading car t-cell therapy portfolio at ash 2024, including positive survival outcomes in both clinical trials and the real-world

Santa monica, calif.--(business wire)--kite, a gilead company (nasdaq: gild), will share 18 presentations, including six oral presentations, demonstrating the strength of its car t-cell therapy portfolio across a spectrum of blood cancers during the 66th american society of hematology (ash) annual meeting and exposition (december 7-10). “our data underscore our commitment to helping people with blood cancers live longer and demonstrate the benefit of car t-cell therapy as a mainstay of blood ca.
CAR Ratings Summary
CAR Quant Ranking